ArticleFrontiers in medicine2026
Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this cross-sectional observational study, we evaluated whether serum and urinary Golgi membrane protein 1 (GOLM1/GP73) could serve as biomarkers for CKD. Chronic kidney disease (CKD) lacks simple biomarkers reflecting both systemic burden and tubular health. GP73 is stress-responsive, but its utility across CKD and acute kidney injury (AKI) has not been systematically evaluated. Methods: We enrolled 32 healthy individuals and 172 kidney disease patients: CKD stages 1-3 ( Results: Serum G73 progressively increased from healthy controls to CKD stages 4-5, with a modest decrease in CKD stage 5D (median: healthy 47.2, CKD1-3 62.2, CKD4-5 96.1, CKD5D 89.9 ng/mL; Conclusions: Serum G73 independently associates with CKD severity and adds diagnostic value to conventional models, especially for advanced CKD. The contrasting decline in urinary G73 and lack of increased renal tissue expression are consistent with a predominantly extra-renal contribution to circulating G73, while urinary G73 reflects tubular function. Serum and urinary G73 are useful non-invasive biomarkers that could improve CKD staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.